USE OF CAJANOLACTONE A IN PREPARING FORMULATION FOR TREATING ACQUIRED OBESITY AND CONCOMITANT DISEASES THEREOF

• Main Authors: FU, Lin-Chun, SHEN, Xiao-Ling, LUO, Zhuo-Hui, HU, Ying-Jie
• Format: Patent
• Language: Chinese; English; French
• Published: 20.01.2022
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

Disclosed is a use of cajanolactone A in preparing a formulation for treating acquired obesity and concomitant diseases thereof. The inventor discovered unexpectedly in research that the oral intake of cajanolactone A effectively inhibits increases caused by non-congenital factors (high-fat diet or ovarian removal) in weight gain, total body fat percentage, subcutaneous fat percentage and visceral fat percentage of obese animals in obese mouse models, thereby protecting impaired liver function. The oral intake of cajanolactone A also effectively reduces weight gain, average cell diameter, and average cell area of retroperitoneal and inguinal white adipose tissues, significantly improving liver tissue fat deposition and liver function. Cajanolactone A has very broad clinical application prospects when used as a formulation for treating or improving obesity and obesity-related fatty liver disease caused by a high-fat high-calorie diet, or when used as a formulation for treating or improving obesity of postmenop